Defence Therapeutics Inc Class A

As of March 31, 2026, Defence Therapeutics Inc Class A carries a market capitalization of 45.35M, placing it among publicly traded companies globally. Its enterprise value stands at 43.96M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of March 31, 2026, Defence Therapeutics Inc Class A has 75.59M shares outstanding.

These figures are as of March 31, 2026.

As of March 31, 2026, Defence Therapeutics Inc Class A maintains a current ratio of 3.37, meaning it holds 3.4x the short-term assets needed to cover near-term liabilities.

As of the close on October 14, 2026, Defence Therapeutics Inc Class A's stock has declined approximately 58.14% over the past 52 weeks. The 50-day moving average sits at 0.73, while the 200-day moving average is 1.26.

As of March 31, 2026, Defence Therapeutics Inc Class A holds 2.95M in cash and equivalents against 1.56M in total debt, resulting in a net debt position of -1.39M. Total book value stands at 5.41M, with working capital of 2.30M providing operational flexibility.